METASTATIC SMALL CELL CARCINOMA OF THE URINARY BLADDER TREATED WITH SYSTEMIC CHEMOTHERAPY INCLUDING AN AMRUBICIN; A CASE REPORT

DOI Web Site Web Site PubMed 9 References
  • Naito Akihiro
    Department of Urology, Tokyo Metropolitan Tama Medical Center
  • Matsumoto Akihiko
    Department of Urology, Tokyo Metropolitan Tama Medical Center
  • Odani Keiko
    Department of Urology, Tokyo Metropolitan Tama Medical Center
  • Sato Yujiro
    Department of Urology, Tokyo Metropolitan Tama Medical Center
  • Azuma Takeshi
    Department of Urology, Tokyo Metropolitan Tama Medical Center
  • Ishizawa Mitugu
    Department of Pathology, Tokyo Metropolitan Tama Medical Center
  • Nagase Yasushi
    Department of Urology, Tokyo Metropolitan Tama Medical Center
  • Oshi Masaya
    Department of Urology, Tokyo Metropolitan Tama Medical Center
  • Homma Yukio
    Department of Urology, Graduate School of Medicine, The University of Tokyo

Bibliographic Information

Other Title
  • 膀胱小細胞癌に対するアムルビシン治療経験例
  • 症例報告 膀胱小細胞癌に対するアムルビシン治療経験例
  • ショウレイ ホウコク ボウコウ ショウサイボウガン ニ タイスル アムルビシン チリョウ ケイケンレイ

Search this article

Abstract

<p>We report a 59-year-old male patient with metastatic small cell carcinoma of the bladder treated with systemic chemotherapy including an amrubicin. The patient was referred to our hospital complaining of macrohematuria. A cytoscopy revealed a non-papillary, broad-based tumor extending from the right to the posterior wall of the bladder. A computed tomography showed bilateral hydronephrosis caused by the bladder tumor and multiple metastases to the para-aortic and common iliac lymph nodes. The histopathological findings following a transurethral resection of the bladder tumor revealed a T2N3M1, LYM, stage IV small cell carcinoma. We administered two courses of systemic chemotherapy consisting of cisplatin (CDDP) plus an etoposide (VP-16), a first-line treatment usually administered to patients with small cell carcinoma of the lung. We then administered second-line chemotherapy consisting of CDDP plus an irinotecan. When the first and second-line therapies failed to halt progression of the disease, we decided to use amrubicin as the third-line therapy concomitant with radiotherapy for local control. Although the NSE (neuron-specific enolase) value decreased, the patient died 11 months after the initial examination. To our knowledge, this is the first case in which small cell carcinoma of the bladder was treated with amrubicin.</p>

Journal

References(9)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top